Peptides for tumour therapy and diagnosis: current status and future directions.
The use of peptides as targeting tools has been validated in different applications. In particular radiolabelled peptides with adequate stability, receptor-binding properties and biokinetic behaviour have been investigated as an important class of radiopharmaceuticals for cancer pathology imaging and therapy. This review focuses on recent progress in design and synthetic modifications of small biologically active peptides used in diagnosis and therapy. In particular, we report the current development and optimization of suitable peptides for targeting three relevant biological receptors (CCK, somatostatin, and integrin receptors) involved in specific tumour diseases.
Zaccaro
Laura
L
Department of Biological Sciences, University of Naples Federico II, via Mezzocannone 16, 80134, Napoli, Italy.
Del Gatto
Annarita
A
Pedone
Carlo
C
Saviano
Michele
M
D000595:Amino Acid Sequence; D000818:Animals; D002766:Cholecystokinin / Q000031:analogs & derivatives; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D016023:Integrins / Q000378:metabolism; D008969:Molecular Sequence Data; D009369:Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000628:therapy*; D010455:Peptides / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics / Q000627:therapeutic use; D011949:Receptors, Cholecystokinin / Q000378:metabolism; D017481:Receptors, Somatostatin / Q000378:metabolism; D013004:Somatostatin / Q000031:analogs & derivatives
D016023:Integrins; D010455:Peptides; D019275:Radiopharmaceuticals; D011949:Receptors, Cholecystokinin; D017481:Receptors, Somatostatin; D013004:Somatostatin; D002766:Cholecystokinin